Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Hepagene: Phase II data; Phase III

MDV reported that its 103-patient Pacific Rim Phase II trial of Hepagene showed that the product reduced levels of replicating HBV

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE